Aclarion, Inc. (ACON)
| Market Cap | 2.02M |
| Revenue (ttm) | 75,404 |
| Net Income (ttm) | -4.91M |
| Shares Out | 7.15M |
| EPS (ttm) | -8.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,891 |
| Open | 0.292 |
| Previous Close | 0.275 |
| Day's Range | 0.275 - 0.292 |
| 52-Week Range | 0.267 - 25.600 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2024 |
About ACON
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was inco... [Read more]
Financial Performance
In 2023, Aclarion's revenue was $75,404, an increase of 24.75% compared to the previous year's $60,444. Losses were -$4.91 million, -34.38% less than in 2022.
Financial StatementsNews
Aclarion Announces Closing of $3.0 Million Public Offering
BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers a...
Aclarion Announces Pricing of $3.0 Million Public Offering
BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisi...
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute
Aclarion Announces Reverse Stock Split
BROOMFIELD, CO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of ...
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian...
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain
Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
Partnership aims to include Aclarion's Nociscan surgical decisioning technology within ATEC's AlphaInformatiX platform to better inform spine surgery
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...
Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI
BROOMFIELD, CO, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...
Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually.
Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
The London Clinic is the UK's most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997.
Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
Development of This Program Supports Aclarion's Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy
Aclarion, Inc. Announces Delayed 10-Q Filing
BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers a...
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of Definitiv...
Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023
Nociscan™ is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological low back pain.
Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor
Broomfield, CO, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...
Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023
BROOMFIELD, CO / ACCESSWIRE / February 16, 2023 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprieta...
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain.
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers ...
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor
Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...
Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event
Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers...
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarke...